Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 3:1
Drug Approvals
65
CIMA_AEMPS:40
EMA:15
NMPA:10
Drug Approvals
Belimumab powder for concentrate for solution for infusion
- Product Name
- 倍力腾
- Approval Number
- 国药准字SJ20190032
- Approval Date
- Aug 23, 2024
NMPA
Fluticasone Furoate and Vilanterol Trifenatate Powder for Inhalation (Ⅱ)
- Product Name
- 糠酸氟替卡松维兰特罗吸入粉雾剂(Ⅱ)
- Approval Number
- 国药准字HJ20180044
- Approval Date
- Jun 7, 2023
NMPA
Fluticasone Furoate and Vilanterol Trifenatate Powder for Inhalation（Ⅲ）
- Product Name
- 糠酸氟替卡松维兰特罗吸入粉雾剂(Ⅲ)
- Approval Number
- 国药准字HJ20180045
- Approval Date
- Jun 7, 2023
NMPA
Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation
- Product Name
- 欧乐欣
- Approval Number
- 国药准字HJ20180005
- Approval Date
- Jan 4, 2023
NMPA
Fluticasone Furoate Nasal Spray
- Product Name
- 文适
- Approval Number
- 国药准字HJ20170104
- Approval Date
- Nov 2, 2021
NMPA
Fluticasone Furoate Nasal Spray
- Product Name
- 文适
- Approval Number
- 国药准字HJ20170105
- Approval Date
- Nov 2, 2021
NMPA
Belimumab powder for concentrate for solution for infusion
- Product Name
- 倍力腾
- Approval Number
- S20190033
- Approval Date
- Dec 10, 2019
NMPA
Belimumab powder for concentrate for solution for infusion
- Product Name
- 倍力腾
- Approval Number
- S20190032
- Approval Date
- Dec 10, 2019
NMPA
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 3
1 (100.0%)No trials found
News
No news found